Table 3.
ART outcomes in high responders according to COS protocol (long/antagonist)
| Protocol | Peak E2 ≤3,000 pg/ml | Peak E2 >3,000 pg/ml |
|---|---|---|
| Total pregnancy rate/o.p.u. | Total pregnancy rate/o.p.u. | |
| Agonist (long protocol) | 216/478 (45.1%) | 29/96 (30.2%) |
| Antagonist | 42/138 (30.4%) | 23/52 (44.2%) |
| P = 0.002 | P = 0.12 | |
| Clinical pregnancy rate/o.p.u. | Clinical pregnancy rate/o.p.u. | |
| Agonist (long protocol) | 168/478 (35.1%) | 20/96 (20.8%) |
| Antagonist | 27/138 (19.5%) | 18/52 (34.6%) |
| P = 0.0007 | P = 0.10 | |
| Implantation rate | Implantation rate | |
| Agonist (long protocol) | 255/1,528 (16.6%) | 23/287 (8%) |
| Antagonist | 38/396 (9.5%) | 25/149 (16.7%) |
| P = 0.0006 | P = 0.009 |
Total, clinical pregnancy and implantation rates in high responders (≥12 oocytes retrieved) according to the COS protocol (long vs. antagonist) and E2 peak levels (≤3,000 or >3,000 pg/ml)